---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-047342"
form_type: "8-K"
ticker: "ALNY"
cik: "0001178670"
company_name: "ALNYLAM PHARMACEUTICALS, INC."
filed_at: "2025-10-30T23:59:59+00:00"
generated_at: "2026-05-17T01:15:02.797872+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Alnylam Q3 net product rev $851M (+103% YoY); raises 2025 guidance 10% to $2.95-3.05B

## Summary
- Total net product revenues $851M (+103% YoY); TTR franchise $724M (+135% YoY) led by AMVUTTRA ATTR-CM launch.
- GAAP net income $251M ($1.84 diluted EPS) vs loss of $111.6M; non-GAAP net income $396M ($2.90 EPS).
- 2025 guidance raised: total net product revs $2.95B-$3.05B (10% midpoint increase); TTR rev guidance $2.475B-$2.525B.
- Initiated ZENITH Phase 3 for zilebesiran in hypertension and TRITON-PN Phase 3 for nucresiran in hATTR-PN.
- Appointed Bryan Supran EVP & Chief Legal Officer; issued $661M convertible notes; received subpoena on government price reporting.

## SEC filing metadata
- accession: 0001628280-25-047342
- form_type: 8-K
- ticker: ALNY
- cik: 0001178670
- company_name: ALNYLAM PHARMACEUTICALS, INC.
- filed_at: 2025-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178670/000162828025047342/0001628280-25-047342-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178670/000162828025047342/alny-20251030.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-047342
- JSON: https://secwatch.observer/filing/0001628280-25-047342.json
- Plain text: https://secwatch.observer/filing/0001628280-25-047342.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.